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Background & aims: Immune modulating nutrition (IMN) has been shown to reduce postoperative in-
fectious complications and length of stay in patients with gastrointestinal cancer. Two studies of IMN in
patients undergoing surgery for head and neck cancer also suggested that this treatment might improve
long-term survival and progression-free survival. In the present study, we analysed follow-up data from
our previous randomised controlled trial of IMN, in patients undergoing surgery for oesophagogastric
and pancreaticobiliary cancer, in order to evaluate the long-term impact on survival of postoperative IMN
versus an isocaloric, isonitrogenous control feed.
Methods: This study included patients undergoing surgery for cancers of the pancreas, oesophagus and
stomach, who had been randomised in a double-blind manner to receive postoperative jejunostomy
feeding with IMN (Stresson, Nutricia Ltd.) or an isonitrogenous, isocaloric feed (Nutrison High Protein,
Nutricia) for 10e15 days. The primary outcome was long-term overall survival.
Results: There was complete follow-up for all 108 patients, with 54 patients randomised to each group.
There were no statistically significant differences between groups by demographics [(age, p ¼ 0.63), sex
(p ¼ 0.49) or site of cancer (p ¼ 0.25)]. 30-day mortality was 11.1% in both groups. Mortality in the
intervention group was 13%, 31.5%, 70.4%, 85.2%, 88.9%, and 96.3% at 90 days, and 1, 5, 10, 15 and 20 years
respectively. Corresponding mortality in the control group was 14.8%, 35.2%, 68.6%, 79.6%, 85.2% and
98.1% (p > 0.05 for all comparisons).
Conclusion: Early postoperative feeding with arginine-enriched IMN had no impact on long-term sur-
vival in patients undergoing surgery for oesophagogastric and pancreaticobiliary cancer.
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The 5-year survival rate for oesophagogastric and pan-
creaticobiliary cancers is amongst the worst of all tumour types [1].





ier Ltd. This is an open access articsuppress immune function and increase the risk of infection. Many
patients with oesophagogastric and pancreaticobiliary cancer also
suffer from malnutrition, which impairs immune function and
leads to a higher incidence of postoperative complications, further
impeding recovery.
Enteral feeding formulae containing key immune modulating
nutrients such as L-arginine, L-glutamine, nucleotides, and u-3 fatty
acids have been designed to counteract these impairments in im-
munity as well as to counterbalance the catabolic response to
surgery [2,3].le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Feed composition (key nutrients per litre).
Feed A (Stresson) Feed B
(Nutrison High Protein)
Energy 1250 kcal (5.2 MJ) 1250 kcal (5.2 MJ)
Total Protein 75 g 75 g
Arginine 8.9 g 3.0 g
Glutamine 13.0 g 7.5 g
Cysteine 0.7 g 0.2 g
Total Fat 41.7 g 48.6 g
Long chain triglycerides 24.5 g 29.2 g
Medium chain triglycerides 17.2 g 19.4 g
Eicosapentaenoic acid 0.79 g e
Docosahexaenoic acid 0.3 g e
u6:u3 fatty acid ratio 3.45:1 5:1
Carbohydrate 145 g (46% energy) 129 g (42% energy)
Naþ 50 mmol 34 mmol
Kþ 58 mmol 44 mmol
Osmolalilty (mOsm/kg) 380 270
A. Adiamah, K.E. Rollins, A. Kapeleris et al. Clinical Nutrition 40 (2021) 5482e5485A meta-analysis of 35 randomised control trials (RCT) in pa-
tients, receiving preoperative L-arginine supplemented diets, found
a 41% reduction in infectious complications and a 2-day reduction
in hospital stay [2]. However, despite the apparent protective effect
of perioperative immune modulating nutrition (IMN) many of
these studies have failed to show any improvement in mortality
[2e4]. Our own RCT from 2006 found no difference in 30-day
mortality rate between patients receiving postoperative IMN and
those given a standard isocaloric, isonitrogenous enteral feed [5].
However, two studies in patients undergoing surgery for head and
neck cancers appear to show improved long-term survival in pa-
tients randomised to an arginine-containing feed arm when
compared with controls [6,7].
The aim of this study was to analyse long-term survival from our
previous RCT [5] to determine if arginine supplementation, as part
of postoperative enteral IMN, in patients undergoing surgery for
oesophagogastric and pancreaticobiliary cancer, improved long-
term survival when compared with an isocaloric isonitrogenous
control feed.
2. Methods
The detailed methodology of this study was published in our
original paper [5] and may be summarised as follows:
2.1. Study design and setting
The original prospective, double-blind RCT [5] was set in
Nottingham University Hospitals NHS Trust (Queen's Medical
Centre and City Campuses) and the Royal Derby Hospital. It
included adult patients undergoing elective resection for oeso-
phagogastric and pancreaticobiliary cancer between January
2000 and June 2003. Patients were randomised, using a stratified
minimisation design, to the experimental or control group, which
were the same in terms of disease and body mass index (BMI)
(<19 or 19 kg/m2). Patients with metastatic or unresectable
disease, pregnant patients and those on immunosuppressive
drugs were excluded.
2.2. Clinical management
All patients underwent surgical resection and needle catheter
feeding tubes (Freka® FCJ tube, Fresenius Kabi Ltd., Hamburg,
Germany) were inserted into the proximal jejunum at the time of
the operation.
2.3. Intervention and study groups
Jejunostomy feeding was commenced 4 h after completion of
the operation at a rate of 25 ml/h on day 0 (day of the operation),
50 ml/h on day 1, and 75 ml/h thereafter. Feeds were delivered by
an infusion pump for 20 h/daywith a 4 h rest period, for 10e15 days
after surgery. Group A received the experimental IMN feed (Stres-
son e Nutricia Ltd., Zoetermeer, Netherlands) while Group B
received an isonitrogenous, isocaloric control feed (Nutrison High
Protein e Nutricia Ltd.) (Table 1).
2.4. End-points
The primary end-point of this follow-up study was long-term
survival up to 20 years postoperatively. Deaths were recorded
from the time of surgery to 1 March 2021 for all patients.54832.5. Statistical analysis
All analysis were undertaken using Stata v16.1 (StataCorp, Stata
Statistical Software: Release 16, College Station, Texas, USA). De-
mographic characteristics of the cohort were assessed with the
Student t-test and c2 test. Differences were considered significant
at p < 0.05. Standard survival methods and Cox regression models
were used to define the overall survival.
2.6. Ethics and consent
The ethics committees of the three hospitals involved approved
the study design for the original study [5]. Informed written con-
sent was obtained from each participant prior to enrolment. No
additional permissions were required for evaluation of their overall
survival.
3. Results
Of the 108 patients included, 54 received the IMN feed and 54
received the isocaloric, isonitrogeneous control feed (Table 1).
There were no statistically significant differences in the de-
mographic characteristics of the patients (age, gender, BMI), or site
of primary tumour or hospital of intended surgery (Table 2). The
median follow-up time was 1.88 years (IQR 0.78e6.07-years).
3.1. Mortality
There were no statistically significant differences in mortality at
any of the time periods analysed when the two groups were
compared (Table 3).
3.2. KaplaneMeier survival curves
Analysis of the survival curves with follow up to 20-years,
demonstrated high early mortality with survival rates of less than
25% occurring by the 6th year in both groups. There was no sta-
tistically significant difference in long-term survival and by the
20th year of follow-up only one patient alive in the control group
and two alive in the IMN group (Fig. 1). The hazards ratio (95%
confidence intervals) for mortality was 1.066 (0.71e1.60), in the
IMN group compared with controls. Using Cox regression analysis,
demographic factors, disease characteristics, and hospital location
did not influence the overall survival at any time point.
Table 2
Demographic and disease profile.
Group A (Stresson) n ¼ 54 Group B (Nutrison High Protein) n ¼ 54 P value (Test)
Age [Mean (SE) years] 65.7 (1.4) 66.6 (1.4) 0.63 (Student t-test)
Gender (M:F) 40:14 43:11 0.49 (c2 test)
BMI (<19 kg/m2:19 kg/m2) 4:50 5:49 1.0 (c2 test)
Site of cancer (oesophagus:stomach:pancreas) 36:11:7 28:18:8 0.25 (c2 test)
Hospital (A:B:Ca) 23:19:12 19:21:14 0.73 (c2 test)
a A ¼ Nottingham University Hospitals, Queen's Medical Centre Campus, B¼ Nottingham University Hospitals, City Hospital Campus, C ¼ Royal Derby Hospital.
Table 3
Cumulative mortality.
Mortality IMN Group Control Group p value (c2 test)
30-day 11.1% 11.1% 1.00
90-day 13.0% 14.8% 0.78
1-year 31.5% 35.2% 0.84
4-year 59.3% 61.1% 0.84
5-year 70.4% 68.5% 0.83
10-year 85.2% 79.6% 0.45
15-year 88.9% 85.2% 0.57
20-year 96.3% 98.1% 0.56
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This study found that early postoperative enteral feeding with
arginine-enriched IMN conferred no additional benefit on either
the short or long-term mortality when compared with an isoca-
loric, isonitrogeneous control formula in patients undergoing sur-
gery for oesophagogastric and pancreaticobiliary cancer.
The benefits of IMN have been well described and include re-
ductions in postoperative infectious complications and hospital
lengthof stay [2,3,8]. Thedirect impactof IMNonboth short-termand
long-termmortality is less clear. Few RCTs in gastrointestinal surgery
that investigate IMN were powered to identify a difference with
mortality as the primary outcome. Nonetheless, several systematic
reviews and meta-analysis in gastrointestinal surgery, have consis-
tently shownno difference inmortality between the IMNand control
groups [2,3,8]. One double-blind RCT in malnourished patients un-
dergoing head and neck cancer surgery, who were given pre- and
postoperative arginine enhanced IMN with a more than 10-year
follow-up, found significantly improved long-term overall survival
and long-term disease specific survival in patients who received an
arginine enriched enteral formula compared with controls [6]. That
study was, however, very small, with only 32 patients. At the time of
thatpublication, all 15patients in thecontrolgroupand14/17patientsFig. 1. KaplaneMeier curves showing cumulative postoperative survival in the im-
mune modulating nutrition (IMN) and isocaloric, isonitrogenous (control) groups
(p ¼ 0.76).
5484in the arginine group had died. Also, although the original study [9]
thatprecededthe long-termsurvival analysis [6] stated that therewas
no arginine in the feed received by the control group, that feed in fact
contained casein which has between 1.9 and 4.7 g arginine/100 g
casein [10].Aphase IIImulticentreRCTcomparinganoral IMNwithan
isonitrogenous, isocaloric control supplement in 180 patients un-
dergoingsurgeryandadjuvant chemo-and radiotherapy forheadand
neck cancer did not find any appreciable benefit on their primary end
point, which was rate of grade 3 and 4 acute mucosal toxicity [7].
However, ina separate analysisof the subgroupofpatientswithahigh
(75%) compliance, both overall (81% vs. 61%) and progression-free
survival (73% vs. 50%) were significantly greater in the experimental
group than in the controls.
Our study, with a sample size of 108 demonstrated no significant
difference in short- or long-term mortality. However, the overall
volume of feed delivered was considerably lower than the target
amount, but there was no statistically significant difference be-
tween the feed volumes delivered to each group [5]. Nevertheless,
no meta-analysis has demonstrated a survival advantage with
arginine-enriched IMN [2,3,8].
Ouroriginal study [5], onwhich this long-termanalysiswas based,
was double-blind and stratified according to disease and BMI to
ensure that operation type anddegree ofmalnutritionwere similar in
the treatment and control groups and did not influence the outcome.
However, there are some limitations thatwarrant further exploration.
Firstly, the control feedwas not completely inert as it contained some
arginine albeit much less than the treatment feed (Table 1). It is un-
certain if this amount of argininewould have been sufficient to affect
the outcome. Additionally, whilst the IMN used in our study was
Stresson, a study that reported survival benefit used Impact® (Nestle,
Vevey, Switzerland)which, in addition to arginine andu-3 fatty acids
has nucleotides but no glutamine [7]. Differences in the composition
of thedifferententeral feeds availablemake itdifficult to compareone
with another. Finally, the timing of early enteral nutrition could also
be important. A meta-analysis of 16 studies found that arginine-
containing IMN (Impact®) given for 5e7 days before surgery resul-
ted in lessmorbidity after elective surgery for gastrointestinal cancer,
albeit not in improved short-term survival [8]. The total amount of
IMNadministeredand theplasma concentration of immunonutrients
achievedmayalso be important in terms of effectiveness. Because the
tolerance to feeding is greater preoperatively than in the early post-
operativeperiod, the amountof feed that canbeadministered in trials
of just postoperative feeding could possibly be less than required to
have a significant effect. Therefore, the findings of this study, which
relates to postoperative feeding cannot necessarily be extrapolated to
IMN feeding in the preoperative setting, which in itself warrants a
separate investigation.
Despite, and perhaps because of all these possible shortcomings
of our study and those of others, there is currently very little evi-
dence upon which to base a recommendation that, in patients
undergoing major surgery for cancer, feeds containing extra im-
mune modulating nutrients have any benefit in terms of mortality,
either in the short-term or long-term, over standard feeds aimed at
treating or preventing malnutrition and its consequences.
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